# Phase II Dutasteride in Combination With CAB vs CAB in SDC

> **NCT05513365** · PHASE2 · RECRUITING · sponsor: **Radboud University Medical Center** · enrollment: 26 (estimated)

## Conditions studied

- Salivary Duct Carcinoma

## Interventions

- **DRUG:** Goserelin 10.8 mg
- **DRUG:** Bicalutamide 50 mg
- **DRUG:** Dutasteride 0.5 mg

## Key facts

- **NCT ID:** NCT05513365
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-27
- **Primary completion:** 2025-09
- **Final completion:** 2027-09
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2025-06-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05513365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05513365, "Phase II Dutasteride in Combination With CAB vs CAB in SDC". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT05513365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*